Skip to main content
2025 Canadian Cardiovascular Congress Main banner
Session Evaluation

HUB TALK

Clinical Research

Coronary Artery Disease

Cardiology

NETWORKING LUNCH BREAK - POSTERS, EXHIBITS AND HUBTALKS

HT-4 - COLCHICINE IN CORONARY DISEASE: EVIDENCE, GUIDELINES, AND CLINICAL PRACTICE

Thursday, October 23, 2025
1:40pm - 2:00pm ET
Room: Theatre 3

Sponsored By 
Explore the latest evidence on low-dose colchicine in CAD. This focused session reviews key trials, guideline updates, and real-world tips to integrate colchicine into secondary prevention. Practical insights for today’s cardiovascular care.Low-dose colchicine has emerged as a promising agent in the secondary prevention of coronary artery disease (CAD), supported by a growing body of clinical evidence and guideline endorsements.

This session will provide a focused review of the clinical trial data and meta-analyses, examine the safety and tolerability profile of colchicine, and offer practical strategies for incorporating it into cardiovascular care. Drawing on both evidence and clinical experience, attendees will gain key insights to optimize treatment for patients with residual inflammatory risk.

Learning Objectives:

At the end of this session participants will be able to:
  • Summarize the latest clinical evidence supporting the use of low-dose colchicine for secondary prevention in patients with coronary artery disease (CAD).
  • Discuss the tolerability and safety of colchicine therapy.
  • Provide practical clinical pearls for integrating colchicine into secondary prevention strategies for CAD, drawing on trial data, meta-analyses, guidelines, and expert experience.